Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: A phase i pilot study

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Perroud Jr , Maurício W ^a   Honma, Helen N ^a   Barbeiro, Aristáteles S ^a   Gilli, Simone C O ^a   Almeida, Maria T ^a   Vassallo, José ^a   Saad, Sara T O ^a   Zambon, Lair ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CEFEPIME; CISPLATIN; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HLA A2 ANTIGEN; PACLITAXEL; CANCER VACCINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANEMIA; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEASIBILITY STUDY; FEMALE; GRANULOCYTOPENIA; HUMAN; HYPONATREMIA; IMMUNE RESPONSE; IMMUNIZATION; LEUKAPHERESIS; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADOPTIVE IMMUNOTHERAPY; CLINICAL TRIAL; DENDRITIC CELL; IMMUNOLOGY; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TREATMENT OUTCOME;

AGED; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 79958861493     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-65     Document Type: Article

References (17)

1. Non-small-cell lung cancer vaccine therapy: a concise review. D O'Mahony S Kummar ME Gutierrez, J Clin Oncol 2005 23 9022 9028 10.1200/JCO.2005.02.3101 16219932 (Pubitemid 46211486)
2. Estimativa 2010 - Incidência de Cncer no Brasil - 2010 - INCA. http://www.inca.gov.br/estimativa/2010/index.asp?link=tabelaestados.asp&UF= BR
3. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. JR Molina P Yang SD Cassivi SE Schild AA Adjei, Mayo Clinic Proceedings 2008 83 584 594 10.4065/83.5.584 18452692 (Pubitemid 351720831)
4. High frequency of immature dendritic cells and altered in situ production of interleukin-4 and tumor necrosis factor-alpha in lung cancer. RB Baleeiro LB Anselmo FA Soares CAL Pinto O Ramos JL Gross F Haddad RN Younes MY Tomiyoshi PC Bergami-Santos JAM Barbuto, Cancer Immunol Immunother 2008 57 1335 1345 10.1007/s00262-008-0468-7 18286287
5. CD1c+ and CD303+ dendritic cells in peripheral blood, lymph nodes and tumor tissue of patients with non-small cell lung cancer. J Tabarkiewicz P Rybojad A Jablonka J Rolinski, Oncol Rep 2008 19 237 243 18097601 (Pubitemid 351176155)
6. The new lung cancer staging system. FC Detterbeck DJ Boffa LT Tanoue, Chest 2009 136 260 271 10.1378/chest.08-0978 19584208
7. Toxicity and response criteria of the Eastern Cooperative Oncology Group. MM Oken RH Creech DC Tormey J Horton TE Davis ET McFadden PP Carbone, Am J Clin Oncol 1982 5 649 655 10.1097/00000421-198212000-00014 7165009 (Pubitemid 13149996)
8. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther, J Natl Cancer Inst 2000 92 205 216 10.1093/jnci/92.3.205 10655437
9. ctcaev3.pdf (objeto application/pdf). http://ctep.cancer.gov/ protocoldevelopment/electronic-applications/docs/ctcaev3.pdf
10. SEER Cancer Statistics Review, 1975-2007. SF Altekruse CL Kosary M Krapcho N Neyman R Aminou W Waldron J Ruhl N Howlader Z Tatalovich H Cho A Mariotto MP Eisner DR Lewis K Cronin HS Chen EJ Feuer DG Stinchcomb BK Edwards, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975-2007/ based on November 2009 SEER data submission, posted to the SEER web site, 2010
11. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. E Hirschowitz T Foody G Hidalgo J Yannelli, Lung Cancer 2007 57 365 372 10.1016/j.lungcan.2007.04.002 17509725 (Pubitemid 47285427)
12. Autologous Dendritic Cell Vaccines for Non-Small-Cell Lung Cancer. EA Hirschowitz, Journal of Clinical Oncology 2004 22 2808 2815 10.1200/JCO.2004.01. 074 15254048 (Pubitemid 41079898)
13. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. DE Avigan B Vasir DJ George WK Oh MB Atkins DF McDermott PW Kantoff RA Figlin MJ Vasconcelles Y Xu D Kufe RM Bukowski, J Immunother 2007 30 749 761 10.1097/CJI.0b013e3180de4ce8 17893567 (Pubitemid 47480758)
14. Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer. S Um YJ Choi H Shin CH Son Y Park MS Roh YS Kim YD Kim S Lee MH Jung MK Lee C Son PJ Choi J Chung C Kang E Lee, Lung Cancer 2010 70 188 194 10.1016/j.lungcan.2010.02.006 20223553
15. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. A Berntsen R Trepiakas L Wenandy PF Geertsen P thor Straten MH Andersen AE Pedersen MH Claesson T Lorentzen JS Johansen IM Svane, J Immunother 2008 31 771 780 10.1097/CJI.0b013e3181833818 18779742
16. A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. EJ Gowans S Roberts K Jones I Dinatale PA Latour B Chua EMY Eriksson R Chin S Li DM Wall RL Sparrow J Moloney M Loudovaris R Ffrench HM Prince D Hart W Zeng J Torresi LE Brown DC Jackson, J Hepatol 2010 53 599 607 10.1016/j.jhep.2010.05.007 20667615
17. Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage D0 Prostate Cancer. DG McNeel EJ Dunphy JG Davies TP Frye LE Johnson MJ Staab DL Horvath J Straus D Alberti R Marnocha G Liu JC Eickhoff G Wilding, Journal of Clinical Oncology 2009 27 4047 4054 10.1200/JCO.2008.19.9968 19636017